Cargando…
Treatment for COVID-19—a cohort study from Northern Italy
Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of to...
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545945/ https://www.ncbi.nlm.nih.gov/pubmed/34697322 http://dx.doi.org/10.1038/s41598-021-00243-4 |
| _version_ | 1784590094191034368 |
|---|---|
| author | Guglielmetti, Lorenzo Aschieri, Daniela Kontsevaya, Irina Calabrese, Francesco Donisi, Alessandra Faggi, Alberto Ferrante, Patrizia Fronti, Elisa Gerna, Laura Leoni, Maria Cristina Paolillo, Franco Ratti, Giovanna Ruggieri, Alessandro Sacchini, Daria Scotti, Marta Valdatta, Caterina Stabile, Marco Taliani, Gloria Codeluppi, Mauro |
| author_facet | Guglielmetti, Lorenzo Aschieri, Daniela Kontsevaya, Irina Calabrese, Francesco Donisi, Alessandra Faggi, Alberto Ferrante, Patrizia Fronti, Elisa Gerna, Laura Leoni, Maria Cristina Paolillo, Franco Ratti, Giovanna Ruggieri, Alessandro Sacchini, Daria Scotti, Marta Valdatta, Caterina Stabile, Marco Taliani, Gloria Codeluppi, Mauro |
| author_sort | Guglielmetti, Lorenzo |
| collection | PubMed |
| description | Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of tocilizumab and of high doses of low molecular weight heparin, but not of antivirals (either alone or in combination), azithromycin, and any corticosteroid, was independently associated with lower mortality. Our results support further clinical evaluation of high doses of low molecular weight heparin and tocilizumab as COVID-19 therapeutics. |
| format | Online Article Text |
| id | pubmed-8545945 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85459452021-10-27 Treatment for COVID-19—a cohort study from Northern Italy Guglielmetti, Lorenzo Aschieri, Daniela Kontsevaya, Irina Calabrese, Francesco Donisi, Alessandra Faggi, Alberto Ferrante, Patrizia Fronti, Elisa Gerna, Laura Leoni, Maria Cristina Paolillo, Franco Ratti, Giovanna Ruggieri, Alessandro Sacchini, Daria Scotti, Marta Valdatta, Caterina Stabile, Marco Taliani, Gloria Codeluppi, Mauro Sci Rep Article Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of tocilizumab and of high doses of low molecular weight heparin, but not of antivirals (either alone or in combination), azithromycin, and any corticosteroid, was independently associated with lower mortality. Our results support further clinical evaluation of high doses of low molecular weight heparin and tocilizumab as COVID-19 therapeutics. Nature Publishing Group UK 2021-10-25 /pmc/articles/PMC8545945/ /pubmed/34697322 http://dx.doi.org/10.1038/s41598-021-00243-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Guglielmetti, Lorenzo Aschieri, Daniela Kontsevaya, Irina Calabrese, Francesco Donisi, Alessandra Faggi, Alberto Ferrante, Patrizia Fronti, Elisa Gerna, Laura Leoni, Maria Cristina Paolillo, Franco Ratti, Giovanna Ruggieri, Alessandro Sacchini, Daria Scotti, Marta Valdatta, Caterina Stabile, Marco Taliani, Gloria Codeluppi, Mauro Treatment for COVID-19—a cohort study from Northern Italy |
| title | Treatment for COVID-19—a cohort study from Northern Italy |
| title_full | Treatment for COVID-19—a cohort study from Northern Italy |
| title_fullStr | Treatment for COVID-19—a cohort study from Northern Italy |
| title_full_unstemmed | Treatment for COVID-19—a cohort study from Northern Italy |
| title_short | Treatment for COVID-19—a cohort study from Northern Italy |
| title_sort | treatment for covid-19—a cohort study from northern italy |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545945/ https://www.ncbi.nlm.nih.gov/pubmed/34697322 http://dx.doi.org/10.1038/s41598-021-00243-4 |
| work_keys_str_mv | AT guglielmettilorenzo treatmentforcovid19acohortstudyfromnorthernitaly AT aschieridaniela treatmentforcovid19acohortstudyfromnorthernitaly AT kontsevayairina treatmentforcovid19acohortstudyfromnorthernitaly AT calabresefrancesco treatmentforcovid19acohortstudyfromnorthernitaly AT donisialessandra treatmentforcovid19acohortstudyfromnorthernitaly AT faggialberto treatmentforcovid19acohortstudyfromnorthernitaly AT ferrantepatrizia treatmentforcovid19acohortstudyfromnorthernitaly AT frontielisa treatmentforcovid19acohortstudyfromnorthernitaly AT gernalaura treatmentforcovid19acohortstudyfromnorthernitaly AT leonimariacristina treatmentforcovid19acohortstudyfromnorthernitaly AT paolillofranco treatmentforcovid19acohortstudyfromnorthernitaly AT rattigiovanna treatmentforcovid19acohortstudyfromnorthernitaly AT ruggierialessandro treatmentforcovid19acohortstudyfromnorthernitaly AT sacchinidaria treatmentforcovid19acohortstudyfromnorthernitaly AT scottimarta treatmentforcovid19acohortstudyfromnorthernitaly AT valdattacaterina treatmentforcovid19acohortstudyfromnorthernitaly AT stabilemarco treatmentforcovid19acohortstudyfromnorthernitaly AT talianigloria treatmentforcovid19acohortstudyfromnorthernitaly AT codeluppimauro treatmentforcovid19acohortstudyfromnorthernitaly |